Competency profile of locally manufactured clopidogrel lowplat and foreign manufactured clopidogrel plavix in patients of suspected ischemic heart disease [CLAP-IHD]
JPMA-Journal of Pakistan Medical Association. 2005; 55 (10): 443-448
en Inglés
| IMEMR
| ID: emr-72609
ABSTRACT
The primary objective of this study was to test the hypothesis that the antiplatelet effects of loading dose of locally manufactured clopidogrel Lowplat referred as drug [B] 600 mg [8 tablets] given once is comparable to the antiplatelet effects of loading dose of foreign manufactured clopidogrel Plavix referred as drug [A] 600 mg [8 tablets] given once in patients with suspected ischemic heart disease. This was a double blind, randomized, cross over, study, to compare the safety and efficacy of study drug [B] versus [A] in adult subjects suffering from suspected ischemic heart disease presented at National Institute of Cardiovascular Disease [NICVD], Karachi. Mean platelet aggregation inhibition by drug [B] was 60.7% [p<0.001], while with drug [A] it was 57.8% [p<0.001], using 20 micro mol/L ADP, which is statistically significant and comparable. Clopidogrel 600 mg as loading dose was well tolerated. Both drugs were equally effective in reducing the platelet aggregation. CLAP-IHD confirmed that drug [B] and [A] are equally effective and comparable antithrombotics in Pakistani population. The cost benefit of drug [B] should be made beneficial to the patients
Buscar en Google
Índice:
IMEMR (Mediterraneo Oriental)
Asunto principal:
Inhibidores de Agregación Plaquetaria
/
Tecnología Farmacéutica
/
Isquemia Miocárdica
/
Industria Farmacéutica
Límite:
Femenino
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
J. Pak. Med. Assoc.
Año:
2005
Similares
MEDLINE
...
LILACS
LIS